Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Clinical significance of sCD105 in angiogenesis and disease activity in multiple myeloma.

Tsirakis G, Pappa CA, Spanoudakis M, Chochlakis D, Alegakis A, Psarakis FE, Stratinaki M, Stathopoulos EN, Alexandrakis MG.

Eur J Intern Med. 2012 Jun;23(4):368-73. doi: 10.1016/j.ejim.2012.01.012. Epub 2012 Mar 3.

PMID:
22560388
2.

Differential levels of soluble endoglin (CD105) in myeloid malignancies.

Calabrò L, Fonsatti E, Bellomo G, Alonci A, Colizzi F, Sigalotti L, Altomonte M, Musolino C, Maio M.

J Cell Physiol. 2003 Feb;194(2):171-5.

PMID:
12494455
3.

Emerging roles of endoglin/CD105 and angiogenic cytokines for disease development and progression in multiple myeloma patients.

Pappa CA, Alexandrakis MG, Boula A, Psarakis FE, Kolovou A, Bantouna V, Stavroulaki E, Tsirakis G.

Hematol Oncol. 2013 Dec;31(4):201-5. doi: 10.1002/hon.2044. Epub 2013 Apr 11.

PMID:
23576184
4.

Immunohistochemical expression of endoglin offers a reliable estimation of bone marrow neoangiogenesis in multiple myeloma.

Alexandrakis MG, Neonakis IK, Pappa CA, Konsolas I, Kokonozaki M, Vyzoukaki R, Soundoulounaki S, Xekalou A, Sfiridaki K, Tsirakis G.

J Cancer Res Clin Oncol. 2015 Aug;141(8):1503-9. doi: 10.1007/s00432-015-1952-z. Epub 2015 Mar 13.

PMID:
25773125
5.

Abnormal expression of Endoglin and its receptor complex (TGF-β1 and TGF-β receptor II) as early angiogenic switch indicator in premalignant lesions of the colon mucosa.

Bellone G, Gramigni C, Vizio B, Mauri FA, Prati A, Solerio D, Dughera L, Ruffini E, Gasparri G, Camandona M.

Int J Oncol. 2010 Nov;37(5):1153-65.

PMID:
20878063
6.

Prognostic impact of angiopoietin-2 in multiple myeloma.

Pappa CA, Alexandrakis MG, Boula A, Thanasia A, Konsolas I, Alegakis A, Tsirakis G.

J Cancer Res Clin Oncol. 2014 Oct;140(10):1801-5. doi: 10.1007/s00432-014-1731-2. Epub 2014 Jun 8.

PMID:
24906877
7.

The relation between bone marrow angiogenesis and the proliferation index Ki-67 in multiple myeloma.

Alexandrakis MG, Passam FH, Dambaki C, Pappa CA, Stathopoulos EN.

J Clin Pathol. 2004 Aug;57(8):856-60.

8.

Serum concentrations and clinical significance of soluble CD40 ligand in patients with multiple myeloma.

Tsirakis G, Pappa CA, Psarakis FE, Fragioudaki M, Tsioutis C, Stavroulaki E, Boula A, Alexandrakis MG.

Med Oncol. 2012 Dec;29(4):2396-401. doi: 10.1007/s12032-012-0203-2. Epub 2012 Mar 9.

PMID:
22403003
9.

Elevated serum soluble endoglin (sCD105) decreased during extracorporeal elimination therapy for familial hypercholesterolemia.

Blaha M, Cermanova M, Blaha V, Jarolim P, Andrys C, Blazek M, Maly J, Smolej L, Zajic J, Masin V, Zimova R, Rehacek V.

Atherosclerosis. 2008 Mar;197(1):264-70. Epub 2007 May 30.

PMID:
17540382
10.

Transforming growth factor beta and soluble endoglin in the healthy senior and in Alzheimer's disease patients.

Juraskova B, Andrys C, Holmerova I, Solichova D, Hrnciarikova D, Vankova H, Vasatko T, Krejsek J.

J Nutr Health Aging. 2010 Nov;14(9):758-61.

PMID:
21085906
11.

Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis.

Rajkumar SV, Mesa RA, Fonseca R, Schroeder G, Plevak MF, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Gertz MA, Kyle RA, Russell SJ, Greipp PR.

Clin Cancer Res. 2002 Jul;8(7):2210-6.

12.

The relationship between soluble receptor of interleukin-6 with angiogenic cytokines and proliferation markers in multiple myeloma.

Tsirakis G, Pappa CA, Kaparou M, Boula A, Katsomitrou V, Xekalou A, Kyriakaki S, Alexandrakis MG.

Tumour Biol. 2013 Apr;34(2):859-64. doi: 10.1007/s13277-012-0618-6. Epub 2012 Dec 16.

PMID:
23242610
13.

Serum levels of soluble IL-6 receptor in multiple myeloma as indicator of disease activity.

Papadaki H, Kyriakou D, Foudoulakis A, Markidou F, Alexandrakis M, Eliopoulos GD.

Acta Haematol. 1997;97(4):191-5.

PMID:
9158660
14.

Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis.

Li C, Gardy R, Seon BK, Duff SE, Abdalla S, Renehan A, O'Dwyer ST, Haboubi N, Kumar S.

Br J Cancer. 2003 May 6;88(9):1424-31.

15.

Interleukin-6 in multiple myeloma: correlation with disease activity and Ki-67 proliferation index.

Thaler J, Fechner F, Herold M, Huber H.

Leuk Lymphoma. 1994 Jan;12(3-4):265-71.

PMID:
8167557
16.

Circulating Ki67 positive lymphocytes in multiple myeloma and benign monoclonal gammopathy.

Miguel-Garcia A, Matutes E, Tarin F, Garcia-Talavera J, Miguel-Sosa A, Carbonell F, Catovsky D.

J Clin Pathol. 1995 Sep;48(9):835-9.

17.

Plasma CD105, TGFbeta-1, TGFbeta-3 and the ligand/receptor complexes in children with acute lymphoblastic leukaemia.

Al-Mowallad A, Carr T, Al-Qouzi A, Li C, Byers R, Kumar S.

Anticancer Res. 2006 Jan-Feb;26(1B):543-7.

18.

Role of platelet-derived growth factor-AB in tumour growth and angiogenesis in relation with other angiogenic cytokines in multiple myeloma.

Tsirakis G, Pappa CA, Kanellou P, Stratinaki MA, Xekalou A, Psarakis FE, Sakellaris G, Alegakis A, Stathopoulos EN, Alexandrakis MG.

Hematol Oncol. 2012 Sep;30(3):131-6. doi: 10.1002/hon.1014. Epub 2011 Sep 14.

PMID:
21919032
19.

Monitoring serum levels ELR+ CXC chemokines and the relationship between microvessel density and angiogenic growth factors in multiple myeloma.

Pappa CA, Tsirakis G, Kanellou P, Kaparou M, Stratinaki M, Xekalou A, Alegakis A, Boula A, Stathopoulos EN, Alexandrakis MG.

Cytokine. 2011 Dec;56(3):616-20. doi: 10.1016/j.cyto.2011.08.034. Epub 2011 Sep 21.

PMID:
21940178
20.

The significance of non correlation between interleukin-8 serum levels with bone marrow microvascular density in patients with myeloma multiple.

Pappa CA, Tsirakis G, Boula A, Sfiridaki A, Psarakis FE, Alexandrakis MG, Stathopoulos EN.

Pathol Oncol Res. 2013 Jul;19(3):539-43. doi: 10.1007/s12253-013-9614-4. Epub 2013 Feb 28.

PMID:
23456515

Supplemental Content

Support Center